Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bonyf NVXPAR:MLBON 37 Debt-to-EBITDA is -1.06 as of Dec. 2024. GuruFocus rates XPAR:MLBON with a GF Score™ of 37/100 and a GF Value™ of €8.50 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 475 Medical Devices & Instruments companies, Bonyf NV ranks worse than 210526.11% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Bonyf NV's Debt-to-EBITDA or its related term are showing as below:
XPAR:MLBON'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.88 Med: -0.12 Max: 67
Current: -1.06
During the past 5 years, the highest Debt-to-EBITDA Ratio of Bonyf NV was 67.00. The lowest was -1.88. And the median was -0.12.
XPAR:MLBON's Debt-to-EBITDA is ranked worse than 100% of 475
companies
in the Medical Devices & Instruments industry
Industry Median: 1.63
vs XPAR:MLBON: -1.06
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Bonyf NV Debt-to-EBITDA Related Terms
Bonyf NV Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Bonyf NV's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bonyf NV Debt-to-EBITDA Chart
Bonyf NV Annual Data
Trend
Dec19
Dec20
Dec22
Dec23
Dec24
Debt-to-EBITDA
0.83
67.00
0.00
-1.88
-1.06
Bonyf NV Semi-Annual Data
Dec19
Dec20
Dec22
Dec23
Dec24
Debt-to-EBITDA
0.83
67.00
0.00
-1.88
-1.06
XPAR:MLBON vs ISRG, BDX, MDLN: Debt-to-EBITDA Comparison
For the Medical Instruments & Supplies subindustry, Bonyf NV's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bonyf NV Debt-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bonyf NV's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Bonyf NV's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is one times the quarterly (Dec. 2024) EBITDA data.
Bonyf NV (XPAR:MLBON) has a Debt-to-EBITDA of -1.06 as of Dec. 2024. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bonyf NV. According to the industry distribution chart, Bonyf NV ranks #999999 out of 475 companies in the Medical Devices & Instruments industry.
Is Bonyf NV's Debt-to-EBITDA too high?
Bonyf NV's current Debt-to-EBITDA is -1.06. Based on the distribution chart, Bonyf NV ranks #999999 out of 475 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Bonyf NV has a GF Score™ of 37/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Bonyf NV's Debt-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bonyf NV ranks #999999 out of 475 companies for Debt-to-EBITDA. This places Bonyf NV in the lower half of its industry. The industry median Debt-to-EBITDA is 1.63. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Devices & Instruments company?
The median Debt-to-EBITDA among Medical Devices & Instruments companies is 1.63, based on 475 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Bonyf NV. For the Medical Devices & Instruments industry, the median Debt-to-EBITDA is 1.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bonyf NV's current Debt-to-EBITDA is -1.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bonyf NV stock overvalued right now?
Based on GuruFocus' analysis, Bonyf NV (XPAR:MLBON) is currently considered Possible Value Trap. The stock's GF Value™ is €8.50, compared to a current price of €2.48 — trading 70.8% below its estimated fair value. The current Debt-to-EBITDA is -1.06. Bonyf NV's overall GF Score™ is 37/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Bonyf NV (XPAR:MLBON), the current Debt-to-EBITDA is -1.06 as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Bonyf NV (XPAR:MLBON) Overvalued in 2026?
Based on GuruFocus' analysis, Bonyf NV stock appears to be undervalued.
The current stock price of €2.48 is trading 70.8% below its estimated GF Value™ of €8.50.
GuruFocus considers Bonyf NV to be Possible Value Trap.
Key valuation signals for XPAR:MLBON:
Debt-to-EBITDA: -1.06
GF Value™: €8.50 vs. price of €2.48 (70.8% below fair value)
No single metric tells the full story. See the XPAR:MLBON stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Bonyf NV specializes in developing, producing and selling cutting-edge oral & dental care products. It is a forward-thinking company committed to revolutionizing oral care through innovation and research.
37GF Score
Get the complete analysis for XPAR:MLBON
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:MLBON has been successfully added to your 
